drugset / Trial / NCT00481117

Safety, Tolerability, and Effect of LY2405319 After Multiple Injections in Subjects With Type 2 Diabetes

NCT00481117 ↗

Phase 1 Completed 37 enrolled Eli Lilly and Company
RandomizedSingle-groupDouble-blindTreatment

Summary

This study intends to evaluate how safe and well tolerated the LY2405319 compound is when given to people for 7 days (in Part 1) and 28 days (in Part 2). This study intends to also determine if there is a positive effect on lowering the level of glucose in people with type 2 diabetes.

Timeline

Start
2008-08
Primary completion
—
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject LY2405319 Unknown 1 mg Subcutaneous
Subject LY2405319 Unknown 3 mg Subcutaneous
Subject LY2405319 Unknown 10 mg Subcutaneous
Subject LY2405319 Unknown 20 mg Subcutaneous